Search research articles
Contact Us
Filters
Showing results (541-550 of 565) with videos related to
Page
of 57
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 27, 2009
NCCN clinical practice guidelines in oncology: kidney cancer
Robert J Motzer, Neeraj Agarwal, Clair Beard, et al.
Journal of Medicinal Chemistry
|
November 8, 2021
An Open Drug Discovery Competition: Experimental Validation of Predictive Models in a Series of Novel Antimalarials
Edwin G Tse, Laksh Aithani, Mark Anderson, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology
|
December 15, 2020
Efficacy and safety of elbasvir/grazoprevir in treatment-naive Chinese adults with hepatitis C virus infection: A randomized trial
Lai Wei, Ji Dong Jia, Zhong Ping Duan, et al.
The Lancet. Gastroenterology & Hepatology
|
August 14, 2017
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials
Eric Lawitz, Maria Buti, John M Vierling, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 16, 2011
Kidney cancer
Robert J Motzer, Neeraj Agarwal, Clair Beard, et al.
Nature
|
March 28, 2024
Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF
Sandi Radko-Juettner, Hong Yue, Jacquelyn A Myers, et al.
Nature
|
April 29, 2024
Author Correction: Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF
Sandi Radko-Juettner, Hong Yue, Jacquelyn A Myers, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 12, 2012
Testicular cancer
Robert J Motzer, Neeraj Agarwal, Clair Beard, et al.
The Lancet. Gastroenterology & Hepatology
|
August 14, 2017
Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials
Edward J Gane, Stephen Pianko, Stuart K Roberts, et al.
Chemical Science
|
January 9, 2018
Experiences with a researcher-centric ELN
Katrina A Badiola, Colin Bird, William S Brocklesby, et al.
Page
of 57
Search research articles
Search
Showing results (541-550 of 565) with videos related to
Sort By:
Page
of 57
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 27, 2009
NCCN clinical practice guidelines in oncology: kidney cancer
Robert J Motzer, Neeraj Agarwal, Clair Beard, et al.
Journal of Medicinal Chemistry
|
November 8, 2021
An Open Drug Discovery Competition: Experimental Validation of Predictive Models in a Series of Novel Antimalarials
Edwin G Tse, Laksh Aithani, Mark Anderson, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology
|
December 15, 2020
Efficacy and safety of elbasvir/grazoprevir in treatment-naive Chinese adults with hepatitis C virus infection: A randomized trial
Lai Wei, Ji Dong Jia, Zhong Ping Duan, et al.
The Lancet. Gastroenterology & Hepatology
|
August 14, 2017
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials
Eric Lawitz, Maria Buti, John M Vierling, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 16, 2011
Kidney cancer
Robert J Motzer, Neeraj Agarwal, Clair Beard, et al.
Nature
|
March 28, 2024
Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF
Sandi Radko-Juettner, Hong Yue, Jacquelyn A Myers, et al.
Nature
|
April 29, 2024
Author Correction: Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF
Sandi Radko-Juettner, Hong Yue, Jacquelyn A Myers, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 12, 2012
Testicular cancer
Robert J Motzer, Neeraj Agarwal, Clair Beard, et al.
The Lancet. Gastroenterology & Hepatology
|
August 14, 2017
Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials
Edward J Gane, Stephen Pianko, Stuart K Roberts, et al.
Chemical Science
|
January 9, 2018
Experiences with a researcher-centric ELN
Katrina A Badiola, Colin Bird, William S Brocklesby, et al.
Page
of 57